SMMT
$15.85
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies.
Intraday
Recent News
Is Summit Therapeutics (SMMT) Pricing Reflect Long Term Value After Recent Share Price Swings
If you are wondering whether Summit Therapeutics is still priced mainly on its story or whether the current share price offers more fundamental value, this article will help unpack what the market might be implying. Over the past month the stock has returned 11.8%. Over one year the return sits at a 15.4% decline, and the three year return is very large, reflecting a move of more than 7x. Recent trading interest has been shaped by broad market attention on smaller biotech names and ongoing...
Summit Therapeutics (SMMT) Ends 2025 With Strong Cash Reserves and Increased Clinical Investment
Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the stocks with explosive growth potential. On February 23, Summit Therapeutics reported results for 2025 with a strong financial foundation, reporting ~$713.4 million in cash and no outstanding debt. While GAAP operating expenses for Q4 reached $225 million, this represented a decrease from the previous quarter. Conversely, non-GAAP […]
Summit Therapeutics Inc. (SMMT) Focused on Non-Small Cell Lung Cancer Trial of Ivonescimab
Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the best cancer stocks to invest in now. On February 23, Summit Therapeutics Inc. (NASDAQ:SMMT) reiterated it is progressing with the development of ivonescimab in non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). It’s undertaking multiregional Phase III clinical trials. In addition, the company has engaged GORTEC, […]
Summit Therapeutics Inc (SMMT) Q4 2025 Earnings Call Highlights: Strong Cash Position and ...
Summit Therapeutics Inc (SMMT) ends 2025 with a robust cash reserve and no debt, while advancing its clinical pipeline through strategic partnerships and increased R&D investments.
Summit Therapeutics Inc. Q4 2025 Earnings Call Summary
Moby summary of Summit Therapeutics Inc.'s Q4 2025 earnings call